TY - JOUR
T1 - Altretamine for the treatment of metastatic renal cell carcinoma
T2 - A Hoosier Oncology Group trial
AU - Zon, Robin T.
AU - Mcclean, John
AU - Helman, Douglas
AU - Ansari, Rafat
AU - Picus, Joel
AU - Sandler, Alan
AU - Williams, Stephen D.
AU - Loehrer, Patrick J.
PY - 2001
Y1 - 2001
N2 - Thirty patients with advanced renal cell carcinoma were treated on a phase 11 trial with altretamine. Altretamine was administered orally at a dosage of 260 mg/m2 days 1 through 14 with cycles repeated every 28 days. Nausea and vomiting were the most common toxicities. Ten percent (3 of 30) experienced Grade 3 gait abnormalities. None of the thirty evaluable patients achieved a complete or partial response. In summary, altretamine did not show antitumor activity in the treatment of advanced renal cell carcinoma.
AB - Thirty patients with advanced renal cell carcinoma were treated on a phase 11 trial with altretamine. Altretamine was administered orally at a dosage of 260 mg/m2 days 1 through 14 with cycles repeated every 28 days. Nausea and vomiting were the most common toxicities. Ten percent (3 of 30) experienced Grade 3 gait abnormalities. None of the thirty evaluable patients achieved a complete or partial response. In summary, altretamine did not show antitumor activity in the treatment of advanced renal cell carcinoma.
KW - Altretamine
KW - Renal cell carcinoma
UR - https://www.scopus.com/pages/publications/0034845091
U2 - 10.1023/A:1010620601431
DO - 10.1023/A:1010620601431
M3 - Article
C2 - 11561679
AN - SCOPUS:0034845091
SN - 0167-6997
VL - 19
SP - 229
EP - 231
JO - Investigational New Drugs
JF - Investigational New Drugs
IS - 3
ER -